David D. Yang
YOU?
Author Swipe
View article: Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial Open
Patients with hormone receptor-positive (HR + )/HER2- breast cancer may benefit from neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy. The effect of chemotherapy or ICI run-in before combination therapy in this population is…
View article: Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate Cancer
Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate Cancer Open
Risk stratification in localized prostate cancer (PCa) remains imprecise. Computational pathology has emerged as an attractive option for improving risk stratification, but current approaches either lack interpretability or focus solely on…
View article: Implementing a context-augmented large language model to guide precision cancer medicine
Implementing a context-augmented large language model to guide precision cancer medicine Open
The rapid expansion of molecularly informed therapies in oncology, coupled with evolving regulatory FDA approvals, poses a challenge for oncologists seeking to integrate precision cancer medicine into patient care. Large Language Models (L…
View article: Impact of Cribriform Pattern on Progression-Free Survival After Radical Prostatectomy in Gleason Score 8-10 Prostate Cancer
Impact of Cribriform Pattern on Progression-Free Survival After Radical Prostatectomy in Gleason Score 8-10 Prostate Cancer Open
Background: Although extensive research highlights the detrimental effect of cribriform pattern 4 (CP4) on survival in non-high-risk prostate cancer (PC), its prognostic significance in high-risk PC is not well understood. Methods: The ind…
View article: DirectHRD enables sensitive scar-based classification of homologous recombination deficiency
DirectHRD enables sensitive scar-based classification of homologous recombination deficiency Open
Homologous recombination deficiency (HRD) is a predictive biomarker for efficacy of PARP (poly ADP-ribose polymerase) inhibition and platinum chemotherapy for cancer patients but remains challenging to detect. The discovery of patients wit…
View article: Development of a dictionary of information items inspired by common data models to support health research data access requests
Development of a dictionary of information items inspired by common data models to support health research data access requests Open
A network of organizations collaborates to provide services to facilitate multi-regional research across Canada. To streamline the data access process, the network is developing a dictionary of information items (InfoItems), providing a la…
View article: Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer
Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer Open
Prostate cancer has substantial heterogeneity in clinical outcomes and therapeutic responses, posing challenges in predicting disease progression and tailoring treatment strategies. Recent studies have highlighted the potential prognostic …
View article: DirectHRD enables sensitive scar-based classification of homologous recombination deficiency (HRD)
DirectHRD enables sensitive scar-based classification of homologous recombination deficiency (HRD) Open
Homologous recombination deficiency (HRD) is a predictive biomarker for efficacy of PARP inhibition and platinum chemotherapy but remains challenging to detect from low tumor fraction samples such as liquid biopsies. Here, we describe Dire…
View article: Supplemental Table 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Table 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Summary of genetic findings from targeted sequencing of ctDNA and whole exome sequencing (WES) from bone biopsy specimen.
View article: Supplemental Table 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Table 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Time to event (months) clinical endpoints by baseline and change in CD4+/FoxP3- (effector) proportion, CD8+ proportion, CD8+ / CD4+FoxP3- (Treg) ratio
View article: Supplemental Figure 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Radium-223 was administered as 55 kBq/kg q4weeks and pembrolizumab as 200 mg q3weeks. Biopsies were performed pre-treatment and after 8 weeks of treatment.
View article: Supplemental Table 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Table 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Maximum grade adverse events, regardless of attribution. AEs are summarized as n (%) for each maximum grade.
View article: Supplemental Figure 8 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 8 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Immune cell functional states differ in clinical responders compared to non-responders. (A) Heat maps summarizing log2 fold changes resulting from statistical scaffold analysis of functional markers 4-1BB, CD44, CTLA-4, GITR, HLA-DR, ICOS,…
View article: Supplemental Figure 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Consort diagram for status of trial. Progression (PD) includes protocol defined progression and clinical/symptomatic progression per physician.
View article: Supplemental Table 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Table 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Maximum grade adverse events, regardless of attribution. AEs are summarized as n (%) for each maximum grade.
View article: Supplementary File 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplementary File 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Supplementary File 3
View article: Data from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Data from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pe…
View article: Supplemental Figure 8 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 8 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Immune cell functional states differ in clinical responders compared to non-responders. (A) Heat maps summarizing log2 fold changes resulting from statistical scaffold analysis of functional markers 4-1BB, CD44, CTLA-4, GITR, HLA-DR, ICOS,…
View article: Supplementary File 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplementary File 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Supplementary File 1
View article: Supplemental Figure 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Changes in A. CD4+FoxP3- effector cells and B. ratio of CD8+ to CD4+/FoxP3+ (Treg) cells from baseline to 8 weeks on treatment
View article: Supplemental Table 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Table 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Clinical characteristics at time of randomization of PSA responders vs. non-responders
View article: Data from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Data from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pe…
View article: Supplementary File 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplementary File 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Supplementary File 1
View article: Supplemental Figure 7 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 7 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Immunofluorescence staining of PD-L1+ CD68 myeloid cells in the bone biopsies. A. RNAscope staining of DAPI (cyan), CD68 (orange), PD-L1 (magenta), Tim3 (green), TIGIT (white) and overlay of bone marrow metastasis. CD68+ cells that co-expr…
View article: Supplemental Figure 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Swimmer’s plot of treatments received. Number of radium-223 and pembrolizumab doses received are listed to the left and right of the bars, respectively. The brackets “[” and “]” represent the planned break period from radium-223 dosing wit…
View article: Supplemental Table 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Table 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Proportion of patients who experienced any or given category of symptomatic skeletal events by the treatment arms
View article: Supplemental Figure 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Radium-223 was administered as 55 kBq/kg q4weeks and pembrolizumab as 200 mg q3weeks. Biopsies were performed pre-treatment and after 8 weeks of treatment.
View article: Supplemental Figure 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. baseline CD4+FoxP3- (effector) proportion above (high) vs. below (low) median. B. baseline CD8+ propo…
View article: Supplemental Figure 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Figure 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Consort diagram for status of trial. Progression (PD) includes protocol defined progression and clinical/symptomatic progression per physician.
View article: Supplemental Table 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Supplemental Table 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Open
Summary of genetic findings from targeted sequencing of ctDNA and whole exome sequencing (WES) from bone biopsy specimen.